Nara et al's findings suggest that serum IL-6 levels may be a helpful prognostic indicator for clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease, influencing decisions on the intensity of early-phase immunosuppressive treatment (29). This evidence concerns the gene IL6 and dermatomyositis.